Literature DB >> 23112192

Critical role of calcitonin gene-related peptide receptors in cortical spreading depression.

Alessandro Tozzi1, Antonio de Iure, Massimiliano Di Filippo, Cinzia Costa, Stefano Caproni, Antonio Pisani, Paola Bonsi, Barbara Picconi, Letizia M Cupini, Serena Materazzi, Pierangelo Geppetti, Paola Sarchielli, Paolo Calabresi.   

Abstract

Cortical spreading depression (CSD) is a key pathogenetic step in migraine with aura. Dysfunctions of voltage-dependent and receptor-operated channels have been implicated in the generation of CSD and in the pathophysiology of migraine. Although a known correlation exists between migraine and release of the calcitonin gene-related peptide (CGRP), the possibility that CGRP is involved in CSD has not been examined in detail. We analyzed the pharmacological mechanisms underlying CSD and investigated the possibility that endogenous CGRP contributes to this phenomenon. CSD was analyzed in rat neocortical slices by imaging of the intrinsic optical signal. CSD was measured as the percentage of the maximal surface of a cortical slice covered by the propagation of intrinsic optical signal changes during an induction episode. Reproducible CSD episodes were induced through repetitive elevations of extracellular potassium concentration. AMPA glutamate receptor antagonism did not inhibit CSD, whereas NMDA receptor antagonism did inhibit CSD. Blockade of voltage-dependent sodium channels by TTX also reduced CSD. CSD was also decreased by the antiepileptic drug topiramate, but not by carbamazepine. Interestingly, endogenous CGRP was released in the cortical tissue in a calcium-dependent manner during CSD, and three different CGRP receptor antagonists had a dose-dependent inhibitory effect on CSD, suggesting a critical role of CGRP in this phenomenon. Our findings show that both glutamate NMDA receptors and voltage-dependent sodium channels play roles in CSD. They also demonstrate that CGRP antagonism reduces CSD, supporting the possible use of drugs targeting central CGRP receptors as antimigraine agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23112192      PMCID: PMC3503217          DOI: 10.1073/pnas.1215435109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine.

Authors:  Susan D Brain
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

Review 3.  Treatment recommendations for migraine.

Authors:  Stephen D Silberstein
Journal:  Nat Clin Pract Neurol       Date:  2008-07-29

4.  Spreading depression: from serendipity to targeted therapy in migraine prophylaxis.

Authors:  C Ayata
Journal:  Cephalalgia       Date:  2009-10       Impact factor: 6.292

Review 5.  Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine.

Authors:  Stewart J Tepper; Mark J Stillman
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

Review 6.  Recent advances in understanding migraine mechanisms, molecules and therapeutics.

Authors:  Peter J Goadsby
Journal:  Trends Mol Med       Date:  2006-12-01       Impact factor: 11.951

7.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

Review 8.  CGRP and its receptors provide new insights into migraine pathophysiology.

Authors:  Tony W Ho; Lars Edvinsson; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2010-09-07       Impact factor: 42.937

9.  Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists.

Authors:  Iñaki F Trocóniz; Jan-Markus Wolters; Hans Guenter Schaefer; Willy Roth
Journal:  Eur J Pharm Sci       Date:  2004-07       Impact factor: 4.384

10.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

View more
  43 in total

Review 1.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

2.  Intranasally administered IGF-1 inhibits spreading depression in vivo.

Authors:  Yelena Y Grinberg; Lois A Zitzow; Richard P Kraig
Journal:  Brain Res       Date:  2017-09-23       Impact factor: 3.252

Review 3.  Calcium channels and synaptic transmission in familial hemiplegic migraine type 1 animal models.

Authors:  Osvaldo D Uchitel; Carlota González Inchauspe; Mariano N Di Guilmi
Journal:  Biophys Rev       Date:  2013-12-03

Review 4.  Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations.

Authors:  Daniela Pietrobon; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

Review 5.  Calcitonin gene-related peptide (CGRP): a new target for migraine.

Authors:  Andrew F Russo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

6.  CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura.

Authors:  Aaron J Schain; Agustin Melo-Carrillo; Jennifer Stratton; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2019-05-24       Impact factor: 6.167

Review 7.  Targeting CGRP: A New Era for Migraine Treatment.

Authors:  Stephanie Wrobel Goldberg; Stephen David Silberstein
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 8.  Spreading Depression, Spreading Depolarizations, and the Cerebral Vasculature.

Authors:  Cenk Ayata; Martin Lauritzen
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

Review 9.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 10.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.